Baird lowered the firm’s price target on AdaptHealth (AHCO) to $14 from $16 and keeps an Outperform rating on the shares. The firm said the company is delivering in most categories, with strong BS/CF improvement, and overall operational improvement, except for Diabetes. The company’s diabetes business is bad, and it is getting a major overhaul.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AHCO:
- AdaptHealth Reports Q3 2024 Financial Results
- Morning Movers: GlobalFoundries and Apollo Global gain following Q3 results
- AdaptHealth revises FY24 revenue view to $ $3.22B-$3.26B, consensus $3.28B
- AdaptHealth reports Q3 EPS 15c, consensus 17c
- AdaptHealth put volume heavy and directionally bearish
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
